Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

Log in / Sign up

← Back to home

Signalchem Lifesciences Corporation

Clinical trials sponsored by Signalchem Lifesciences Corporation, explained in plain language.

New Two-Pronged attack tested against tough lung cancers

Disease control Terminated

This study tested a new oral drug, SLC-391, given alongside the immunotherapy drug pembrolizumab in people with advanced non-small cell lung cancer (NSCLC). The first part aimed to find a safe dose for the combination. The second part aimed to see if the two drugs together could …

Phase: PHASE1, PHASE2 • Sponsor: SignalChem Lifesciences Corporation • Aim: Disease control

Last updated Apr 04, 2026 05:21 UTC